)
Intellia Therapeutics (NTLA) investor relations material
Intellia Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.HAE regulatory and clinical update
Lonvo-z is under priority FDA review, with a March 10, 2027 PDUFA date; FDA has said so far that an advisory committee is not needed, and review has proceeded without unusual requests.
The CMC review is progressing well through the FDA pilot program; prior FDA engagement helped establish standards for products like this.
HAE data show attacks falling to zero for most patients; all patients across Phase I–III were off long-term prophylaxis, while one outlier with ongoing attacks had essentially normal high-molecular-weight kininogen levels and may have another condition.
On-demand therapy use fell sharply from pretreatment levels; kallikrein knockdown follow-up extends beyond 4 years, with continued monitoring planned.
HAE launch and market access
Survey research found nearly 70% of patients willing to discuss lonvo-z with physicians in the first 6 months post-approval; about two-thirds of physicians expected to prescribe within the first year.
Initial adopters may include both patients seeking better control and well-controlled patients looking to avoid chronic therapy; Phase III outcomes were similar across patient groups.
Payer coverage is the launch rate-limiting step: medical exceptions are expected in the first 3 months, initial contracts and treated patients in months 3–6, and a goal of covering most HAE lives by month 9.
The U.S. launch is the near-term focus; ex-U.S. options include out-licensing or distribution arrangements, to be considered after establishing the U.S. launch. Management interprets cell and gene therapies as excluded from MFN considerations.
Management expects a high-margin, one-time product, citing synthetic manufacturing and established infrastructure; pricing and COGS details were not specified.
TTR program
Following the clinical hold lift, multinational sites are being reactivated; investigator enthusiasm is unchanged, patients remained in the study, and HLA status information has helped inform benefit-risk discussions.
HLA-positive status runs at 10%–12% across the study, varying with ethnicity and geography.
MAGNITUDE-2 enrollment is complete, with enrollment described as roughly 10%–15% above the target of about 60; a 9-month interim is under consideration but is not currently planned.
In Phase I polyneuropathy follow-up through 2 years, some patients stabilized or improved, including several who had progressed on Onpattro; Phase III is placebo-controlled, so direct comparisons with other therapies are not planned.
Cardiomyopathy Phase III enrollment is progressing ahead of schedule; management is evaluating potential study adjustments using external trial results and emphasizing earlier-stage patients with lower NT-proBNP.
- Lonvo-z showed durable HAE control as FDA review and launch preparations advance.NTLA
Study update - Lonvo-z Priority Review targets a Q1 2027 launch amid continued losses and nex-z safety monitoring.NTLA
Q3 2026 - Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects.NTLA
Morgan Stanley 24th Annual Global Healthcare Conference - Strong Phase 3 data and $628.4M cash position support launch plans and ongoing clinical progress.NTLA
Q2 2026 - Accelerated phase III progress in ATTR and HAE, with major data and milestones expected by 2027.NTLA
BofA Securities 2025 Healthcare Conference - Nexi/nex-z achieved deep, durable TTR reduction and clinical stabilization in ATTR amyloidosis.NTLA
Study Update - Strong CRISPR trial progress, $944.7M cash, Q3 net loss $135.7M, late-stage pipeline advancing.NTLA
Q3 2024 - A single 50 mg dose achieved 81% attack reduction and 73% attack-free rate in HAE patients.NTLA
Study Update - Late-stage pipeline progress, restructuring, and cash runway extend operational momentum into 2027.NTLA
Q4 2024
)
)
)
)
)
)
)
)